Skip to main
LGND
LGND logo

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals Inc. demonstrates a strong financial outlook supported by substantial cash inflows, which facilitate ongoing deal-making and enhance the company's compounding business model within the smid-cap biotech sector. The anticipated successful launches of its products Filspari and Ohtuvayre further contribute to revenue growth, alongside stable returns from established contributors. Overall, Ligand's diversified revenue streams, including royalties, license and milestone payments, and sales of its Captisol material, position the company favorably for sustained financial performance.

Bears say

Ligand Pharmaceuticals Inc. faces a negative outlook primarily due to concerns regarding the potential underperformance of its royalty assets and challenges to the intellectual property durability of key products. The risk of clinical-stage royalty assets not receiving approval amplifies uncertainty around future revenue streams, while anticipated less favorable terms in partnerships could further strain their business model. Additionally, commercial partners may encounter unforeseen difficulties, which could hinder overall financial performance and growth prospects for Ligand.

Ligand Pharmaceuticals (LGND) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Buy based on their latest research and market trends.

According to 6 analysts, Ligand Pharmaceuticals (LGND) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $206.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $206.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.